Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

Background: Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn’s disease are established. We investigated its efficacy in ulcerative colitis. Methods: We conducted a randomised placebo controlled trial of infli...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Probert, C S J, Hearing, S D, Schreiber, S, Kühbacher, T, Ghosh, S, Arnott, I D R, Forbes, A
Formato: Artigo
Idioma:Inglês
Publicado: Copyright 2003 by Gut 2003
Assuntos:
Inflammatory Bowel Disease
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1773722/
https://ncbi.nlm.nih.gov/pubmed/12801957
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares